Search
Menu
Home
HTB
2002
October
13
13 October 2002
Contents
Antiretrovirals
US HIV community hold productive meeting with Schering-Plough on new anti-HIV entry inhibitors SCH-C and SCH-D
Notes on Schering-Plough/HIV community meeting held August 28 2002
US FDA announces important changes in amprenavir product labelling
Much lower dose of lamivudine needed for HIV-positive patients on dialysis
Patients discontinuing HAART must be carefully monitored
Treatment access
Excitement over anticipated approval of T-20 is balanced by fears that it will be the most expensive HIV drug yet
GlaxoSmithKline cuts drug prices to 63 countries
Paediatric care
Antiretrovirals have neurologic benefits in children
Early data highlight ribavirin’s anti-adenovirus potential
PK and drug interactions
St John’s Wort interferes with chemotherapy, study shows
Guidelines
Updated recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States
Drug resistance
M184V is associated with decreased development of TAMs
Other news
Integrase inhibitors enter trials in human volunteers
Antiretrovirals could stop HIV epidemic – optimism or realism?
Dutch researchers theorise chimpanzees may have survived AIDS epidemic two million years ago
Majority of HIV patients in San Francisco study use alternative medicines
Early data find HIV patients do well with organ transplants
Thai charity ditches V-1 Immunitor
On the web
ABC of psychological medicine: fatigue
Initial antiretroviral therapy: further insights on when to start and what to use
Antiretroviral therapy in treatment-experienced patients
Update on lipodystrophy…or is it just lipoatrophy?
Opportunistic infections and coinfections: focus on fungi and hepatitis
XI International HIV Drug Resistance Workshop: basic principles and clinical implications; Seville, Spain July 2-5, 2002
Time for T
CD4 cell depletion in AIDS: models for novel therapies
FRAM study and lipodystrophy: lipodystrophy study presented at Barcelona and an interview with the study author Carl Grunfeld
HTB RSS
Early access
Long-acting CAB/RPV in people with suboptimal adherence: IMPALA study results at 48 weeks
17 July 2025
Potential for once-monthly oral PrEP using MK-8527
17 July 2025
Five doses a week could be a safe option for adults: crisis response to ART stock-outs
16 July 2025
5-on 2-off dosing is inferior to continuous ART in BREATHER Plus – but no difference in clinical outcomes
16 July 2025
All early access reports
Current issues
July 2025
June 2025
May 2025
Back issues
Special report
AIDS quilts at the Tate: reflection and also anger
8 July 2025
More from HTB
Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage
Home
i-Base homepage
Donate